ESMO Immuno-Oncology Virtual Congress 2020: Meeting Resources

Patients received intratumoural administration of ipilimumab plus nivolumab that was followed by intracavitary nivolumab plus nivolumab given intravenously

This combination changes “cold” tumour microenvironments to “hot” in Human Papillomavirus-positive malignancies

Metastatic uveal melanoma is a treatment-refractory tumour that is associated with poor prognosis and poses an urgent need for new treatments

Quality of life, as evaluated by patient reported outcomes, was an exploratory endpoint of CheckMate 743

Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy

Immune checkpoint inhibitor treatment is used for tumours with microsatellite instability high or mismatch repair deficiency but not all of these patients respond

Not all eligible patients respond to treatment with an immune checkpoint inhibitor

Pleural effusion was associated with worse patient characteristics, poorer survival and higher early death rates

Life-threatening adverse events have been reported in some patients following immune checkpoint inhibitor treatment for cancer

Data from a propensity-matched survival analysis

Immune-related adverse events due to checkpoint inhibitor treatment can affect any organ and may be linked to ocular adverse events

Previously reported findings suggest that systemic antibiotic exposure may alter the efficacy of treatment with an immune checkpoint inhibitor by impacting the intestinal microbiota

Immunochemotherapy combinations have demonstrated improved efficacy over sole chemotherapy in diverse solid tumours